Curie.Bio
Curie.Bio is a Boston-based biotech venture capital firm founded in 2022 that provides capital and operating support to founders developing novel clinical-stage therapeutics. The firm is backed by tier-1 investors including ARCH, Andreessen Horowitz, and Google Ventures.
- Company typePrivate
- Founded2022
- HeadquartersBoston, United States
- Headcount51–100
- GTM typeB2B
- OfferingServices
Curie.Bio firmographics
Firmographics- Name
- Curie.Bio
- Legal name
- Curie.Bio
- Website
- https://curie.bio
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Curie.Bio is a Boston-based biotech venture capital firm founded in 2022 that provides capital and operating support to founders developing novel clinical-stage therapeutics. The firm is backed by tier-1 investors including ARCH, Andreessen Horowitz, and Google Ventures.
- Ownership category
- akta.pro rank
Curie.Bio industry classification
Industry- Product category
- Biotech Venture Capital
- NAICS
- Funds, Trusts, and Other Financial Vehicles (525), Open-End Investment Funds (525910)
- SIC
- Security Brokers, Dealers & Flotation Companies (6211)
- akta.pro primary industry
- Health & Medical Research Grantmaking Foundations (BPAGAKAL)
- akta.pro secondary industries
- Clinical CROs (Phase I–IV) (HLAGAAAA), Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL)
Keywords
Where Curie.Bio is headquartered
LocationHeadquarters
- HQ city
- Boston
- HQ country
- United States
- HQ region
- North America
Markets served
Curie.Bio business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales
Curie.Bio product offering
Product offeringCore offering
Curie.Bio is a venture capital firm that provides funding and support to founders building clinical-stage biotech companies developing novel therapeutics. The firm operates a hands-on VC model that helps founders discover and develop important new medicines, participating in financing rounds alongside other institutional investors.
Product overview
Curie.Bio is a life science venture capital firm. Based on the source data reviewed, no specific products, services, or technology platforms are described. The website contains standard navigation pages (Home, Our Team, Founder Guide, Life at Curie.Bio, Connect, Careers, Privacy Policy, Terms & Conditions) but no detailed product or service offerings are presented in the scraped content.
Differentiator
Problem solved
Functional benefit
Products and services
- Biotech Founder Funding & Support Venture capital investment and strategic support program for biotech founders building clinical-stage therapeutic companies, providing capital to advance drug development programs.
Companies that use Curie.Bio
Customer profileSegments1 record
Ideal customer profiles1 record
Curie.Bio technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Curie.Bio partnerships and signals
Strategic signalRecent moves5 records
Expansion highlights4 records
Curie.Bio competitors and assessment
Company assessmentDirect peers
- Atlas Venture: Boston-based early-stage biotech venture firm that builds and funds new therapeutic companies from inception — closely analogous to Curie.Bio's co-builder model for founders developing new medicines.
- Flagship Pioneering: Biotech innovation platform that originates and develops new therapeutic companies, operating an 'invention-first' model with embedded R&D support — directly comparable to Curie.Bio's founder-support thesis.
- Third Rock Ventures: Boston-based biotech VC that creates and launches new therapeutic companies with operational involvement from formation — a near-analogous model to Curie.Bio's hands-on approach.
- RA Capital Management: Healthcare and biotech-focused investment firm investing across public and private stages of drug development — directly comparable in therapeutic-area focus and stage.
- OrbiMed: Healthcare-dedicated investment firm funding therapeutics, medical devices, and diagnostics across stages — analogous as a specialist biotech investment platform.
- ARCH Venture Partners: Premier biotech-focused VC firm investing in early-stage life sciences companies; also a known backer of Curie.Bio, making it both a peer and a relationship-relevant investor.
- Section 32: Biotech-focused venture fund investing in early- and growth-stage therapeutics and techbio companies — comparable as a specialist biotech investor.
- Andreessen Horowitz (Bio Fund): a16z's bio/health fund invests across stages of biotech and digital health with operational support — a peer with similar scale ambitions, also an existing LP/backer of Curie.Bio.
- Deerfield Management: Healthcare-focused investment firm that provides capital and operational expertise across the life sciences — analogous as a specialist investor supporting therapeutic development companies.
Broad incumbents
- New Enterprise Associates (NEA): Large diversified VC firm with a substantial healthcare and biotech practice — comparable as a generalist with deep biotech capabilities, though broader in scope than Curie.Bio's specialist focus.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks4 records
Key highlights5 records
Customer concentration
Curie.Bio social profiles
Digital presenceCurie.Bio financial estimates
Financial estimateRevenue estimate
Valuation estimate
Curie.Bio leadership team
Management profileNumber of profiles
Profiles7 records
Curie.Bio funding detail
Funding detailFunding overview
Funding rounds3 records
Investors10 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Curie.Bio M&A and investment
M&A and investmentM&A
Investments13 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Curie.Bio
What does Curie.Bio do?
Curie.Bio is a venture capital firm that provides funding and support to founders building clinical-stage biotech companies developing novel therapeutics. The firm operates a hands-on VC model that helps founders discover and develop important new medicines, participating in financing rounds alongside other institutional investors.
Is Curie.Bio a public or private company?
Curie.Bio is a private company. It is classified as venture growth investor backed and is currently operating.
When was Curie.Bio founded?
Curie.Bio was founded in 2022. It employs 51 to 100 people.
Where is Curie.Bio based?
Curie.Bio is headquartered in Boston, United States, in the North America region.
Who are Curie.Bio's main competitors?
Direct peers on record are Atlas Venture, Flagship Pioneering, Third Rock Ventures, RA Capital Management, OrbiMed, ARCH Venture Partners, Section 32, Andreessen Horowitz (Bio Fund) and Deerfield Management. New Enterprise Associates (NEA) is listed as a broad incumbent.
Does Curie.Bio have an API?
No public API is recorded for Curie.Bio.
What industry is Curie.Bio in?
Curie.Bio's product category is Biotech Venture Capital. Its primary akta.pro industry code is BPAGAKAL, Health & Medical Research Grantmaking Foundations, with a secondary code of HLAGAAAA, Clinical CROs (Phase I–IV). Its NAICS code is 525 and its SIC code is 6211.